作为用于治疗哮喘或慢性阻塞性肺疾病的NLRP3抑制剂的新型化合物。
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
作者信息
Sabnis Ram W
机构信息
Smith, Gambrell & Russell LLP, 1105 W. Peachtree Street NE, Atlanta, Georgia 30309, United States.
出版信息
ACS Med Chem Lett. 2025 Apr 1;16(4):538-539. doi: 10.1021/acsmedchemlett.5c00143. eCollection 2025 Apr 10.
Abstract
Provided herein are novel compounds as NLRP3 inhibitors, pharmaceutical compositions, use of such compounds in treating asthma or COPD, and processes for preparing such compounds.
摘要
本文提供了作为NLRP3抑制剂的新型化合物、药物组合物、此类化合物在治疗哮喘或慢性阻塞性肺疾病中的用途以及制备此类化合物的方法。
相似文献
1
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Apr 1;16(4):538-539. doi: 10.1021/acsmedchemlett.5c00143. eCollection 2025 Apr 10.
2
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Apr 26;16(5):760-761. doi: 10.1021/acsmedchemlett.5c00218. eCollection 2025 May 8.
3
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
4
Novel Compounds as NLRP3 Inhibitors for Treating Cardiovascular Diseases.
ACS Med Chem Lett. 2024 Jul 11;15(8):1184-1185. doi: 10.1021/acsmedchemlett.4c00304. eCollection 2024 Aug 8.
5
Novel Compounds as NLRP3 Inhibitors for Treating Alzheimer's Disease and Parkinson's Disease.
ACS Med Chem Lett. 2024 Jul 29;15(8):1203-1204. doi: 10.1021/acsmedchemlett.4c00343. eCollection 2024 Aug 8.
6
Novel Triazines as NLRP3 Inhibitors for Treating Multiple Diseases.
ACS Med Chem Lett. 2024 Nov 18;15(12):2099-2100. doi: 10.1021/acsmedchemlett.4c00552. eCollection 2024 Dec 12.
7
Pyridazine Compounds as NLRP3 Inhibitors for Treating Parkinson's Disease or Frontotemporal Dementia.
ACS Med Chem Lett. 2024 Nov 7;15(12):2083-2084. doi: 10.1021/acsmedchemlett.4c00523. eCollection 2024 Dec 12.
8
Novel Compounds as CDK2 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 10;16(1):14-15. doi: 10.1021/acsmedchemlett.4c00574. eCollection 2025 Jan 9.
9
Pyrrolopyrazine Compounds as ERK5 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 11;16(1):16-17. doi: 10.1021/acsmedchemlett.4c00580. eCollection 2025 Jan 9.
10
Novel Bicyclic Heterocyclic Compounds as CD73 Inhibitors for Treating Cancer.
ACS Med Chem Lett. 2024 Dec 4;16(1):10-11. doi: 10.1021/acsmedchemlett.4c00565. eCollection 2025 Jan 9.
引用本文的文献
1
Novel Compounds as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Apr 26;16(5):760-761. doi: 10.1021/acsmedchemlett.5c00218. eCollection 2025 May 8.
本文引用的文献
1
Epigenetic targets and their inhibitors in the treatment of idiopathic pulmonary fibrosis.
Eur J Med Chem. 2025 May 5;289:117463. doi: 10.1016/j.ejmech.2025.117463. Epub 2025 Mar 1.
2
Novel Triazine Derivatives as NLRP3 Inhibitors for Treating Asthma or COPD.
ACS Med Chem Lett. 2025 Jan 24;16(2):200-201. doi: 10.1021/acsmedchemlett.5c00020. eCollection 2025 Feb 13.
3
Modulating NLRP3 Inflammasomes in Idiopathic Pulmonary Fibrosis: A Comprehensive Review on Flavonoid-Based Interventions.
Cell Biochem Biophys. 2025 Feb 19. doi: 10.1007/s12013-025-01696-4.
4
The NLRP3 inflammasome in allergic diseases: mechanisms and therapeutic implications.
Clin Exp Med. 2024 Sep 26;24(1):231. doi: 10.1007/s10238-024-01492-z.
5
Inflammasome components as new therapeutic targets in inflammatory disease.
Nat Rev Immunol. 2025 Jan;25(1):22-41. doi: 10.1038/s41577-024-01075-9. Epub 2024 Sep 9.
Zotero 插件